AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...
On Monday, biopharmaceutical giant AbbVie Inc. ABBV agreed to acquire Apogee Therapeutics Inc. APGE in a cash deal valued at ...
Zacks Investment Research on MSN
What sparked the $43B jump in AbbVie's market cap in the past week?
Shares of AbbVie ABBV have gained nearly 11% in the past week, translating to roughly $43 billion in market value. The upside ...
The U.S. Food and Drug Administration is taking North Chicago-based drugmaker AbbVie to task, warning in a recent letter that a migraine medication commercial featuring Serena Williams is “misleading.
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
AbbVie (NYSE:ABBV) announced on Monday that it has agreed to acquire Apogee Therapeutics (NASDAQ:APGE) for $10. 9 billion, ...
AbbVie (NYSE:ABBV) received positive opinions from the European Medicines Agency's CHMP for RINVOQ in severe alopecia areata ...
AbbVie is airing its first TV commercial for its eye drop Vuity four months after its FDA approval and the focus is—well, focus. The eye drop can help improve eyesight and eliminate the need for ...
This marks the fourth R&D milestone achieved under the collaboration, and the second in 2026, reflecting the steady progress of development under the collaboration Under the terms of the agreement, ...
AbbVie’s latest update covers a post‑market study on its CoolSculpting Elite device for non‑surgical fat reduction in the neck, inner thigh, and back/bra areas. The official goal is to track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results